Differential	differential	O	O
impact	impact	O	O
of	of	O	O
immune	immune	O	O
escape	escape	O	O
mutations	mutations	O	O
G145R	g145r	O	O
and	and	O	O
P120	p120	S_chemicals	O
T	t	O	O
on	on	O	O
the	the	O	O
replication	replication	O	O
of	of	O	O
lamivudine-resistant	lamivudine-resistant	O	O
hepatitis	hepatitis	B_chemicals	B_disease
B	b	I_chemicals	B_disease
virus	virus	O	I_disease
e	e	O	O
antigen-positive	antigen-positive	O	O
and	and	O	O
-negative	-negative	O	O
strains	strains	O	S_disease
.	.	O	O

Immune	immune	O	O
escape	escape	O	O
variants	variants	O	O
of	of	O	O
the	the	O	O
hepatitis	hepatitis	B_chemicals	B_disease
B	b	I_chemicals	B_disease
virus	virus	O	I_disease
(	(	O	O
HBV	hbv	O	O
)	)	O	O
represent	represent	O	O
an	an	O	O
emerging	emerging	O	O
clinical	clinical	O	O
challenge	challenge	O	O
,	,	O	O
because	because	O	O
they	they	O	O
can	can	O	O
be	be	O	O
associated	associated	O	O
with	with	O	O
vaccine	vaccine	S_chemicals	O
escape	escape	O	O
,	,	O	O
HBV	hbv	O	O
reactivation	reactivation	O	S_disease
,	,	O	O
and	and	O	O
failure	failure	O	O
of	of	O	O
diagnostic	diagnostic	O	O
tests	tests	O	O
.	.	O	O

Recent	recent	O	O
data	data	O	O
suggest	suggest	O	O
a	a	O	O
preferential	preferential	O	O
selection	selection	O	O
of	of	O	O
immune	immune	O	O
escape	escape	O	O
mutants	mutants	O	O
in	in	O	O
distinct	distinct	O	O
peripheral	peripheral	O	O
blood	blood	O	O
leukocyte	leukocyte	O	O
compartments	compartments	O	O
of	of	O	O
infected	infected	O	O
individuals	individuals	O	O
.	.	O	O

We	we	O	O
therefore	therefore	O	O
systematically	systematically	O	O
analyzed	analyzed	O	O
the	the	O	O
functional	functional	O	O
impact	impact	O	O
of	of	O	O
the	the	O	O
most	most	O	O
prevalent	prevalent	O	O
immune	immune	O	O
escape	escape	O	O
variants	variants	O	O
,	,	O	O
the	the	O	O
sG145R	sg145r	O	O
and	and	O	O
sP120	sp120	O	O
T	t	O	O
mutants	mutants	O	O
,	,	O	O
on	on	O	O
the	the	O	O
viral	viral	O	O
replication	replication	O	O
efficacy	efficacy	O	O
and	and	O	O
antiviral	antiviral	B_chemicals	O
drug	drug	S_chemicals	O
susceptibility	susceptibility	O	O
of	of	O	O
common	common	O	O
treatment-associated	treatment-associated	O	S_disease
mutants	mutants	O	O
with	with	O	O
resistance	resistance	O	O
to	to	O	O
lamivudine	lamivudine	S_chemicals	O
(	(	O	O
LAM	lam	O	O
)	)	O	O
and/or	and/or	O	O
HBeAg	hbeag	S_chemicals	O
negativity	negativity	O	O
.	.	O	O

Replication-competent	replication-competent	O	O
HBV	hbv	O	O
strains	strains	O	S_disease
with	with	O	O
sG145R	sg145r	O	O
or	or	O	O
sP120	sp120	O	O
T	t	O	O
and	and	O	O
LAM	lam	O	O
resistance	resistance	O	O
(	(	O	O
rtM204I	rtm204i	O	O
or	or	O	O
rtL180M/rtM204V	rtl180m/rtm204v	O	O
)	)	O	O
were	were	O	O
generated	generated	O	O
on	on	O	O
an	an	O	O
HBeAg-positive	hbeag-positive	O	O
and	and	O	O
an	an	O	O
HBeAg-negative	hbeag-negative	O	O
background	background	O	O
with	with	O	O
precore	precore	O	O
(	(	O	O
PC	pc	O	O
)	)	O	O
and	and	O	O
basal	basal	O	O
core	core	O	O
promoter	promoter	O	O
(	(	O	O
BCP	bcp	O	O
)	)	O	O
mutants	mutants	O	O
.	.	O	O

The	the	O	O
sG145R	sg145r	O	O
mutation	mutation	O	O
strongly	strongly	O	O
reduced	reduced	O	O
HBsAg	hbsag	S_chemicals	O
levels	levels	O	O
and	and	O	O
was	was	O	O
able	able	O	O
to	to	O	O
fully	fully	O	O
restore	restore	O	O
the	the	O	O
impaired	impaired	O	O
replication	replication	O	O
of	of	O	O
LAM-resistant	lam-resistant	O	O
HBV	hbv	O	O
mutants	mutants	O	O
to	to	O	O
the	the	O	O
levels	levels	O	O
of	of	O	O
wild-type	wild-type	O	O
HBV	hbv	O	O
,	,	O	O
and	and	O	O
PC	pc	O	O
or	or	O	O
BCP	bcp	O	O
mutations	mutations	O	O
further	further	O	O
enhanced	enhanced	O	O
viral	viral	O	O
replication	replication	O	O
.	.	O	O

Although	although	O	O
the	the	O	O
sP120	sp120	O	O
T	t	O	O
substitution	substitution	O	O
also	also	O	O
impaired	impaired	O	O
HBsAg	hbsag	S_chemicals	O
secretion	secretion	O	O
,	,	O	O
it	it	O	O
did	did	O	O
not	not	O	O
enhance	enhance	O	O
the	the	O	O
replication	replication	O	O
of	of	O	O
LAM-resistant	lam-resistant	O	O
clones	clones	O	O
.	.	O	O

However	however	O	O
,	,	O	O
the	the	O	O
concomitant	concomitant	O	O
occurrence	occurrence	O	O
of	of	O	O
HBeAg	hbeag	S_chemicals	O
negativity	negativity	O	O
(	(	O	O
PC/BCP	pc/bcp	O	O
)	)	O	O
,	,	O	O
sP120	sp120	O	O
T	t	O	O
,	,	O	O
and	and	O	O
LAM	lam	O	O
resistance	resistance	O	O
resulted	resulted	O	O
in	in	O	O
the	the	O	O
restoration	restoration	O	O
of	of	O	O
replication	replication	O	O
to	to	O	O
levels	levels	O	O
of	of	O	O
wild-type	wild-type	O	O
HBV	hbv	O	O
.	.	O	O

In	in	O	O
all	all	O	O
clones	clones	O	O
with	with	O	O
combined	combined	O	O
immune	immune	O	O
escape	escape	O	O
and	and	O	O
LAM	lam	O	O
resistance	resistance	O	O
mutations	mutations	O	O
,	,	O	O
the	the	O	O
nucleotide	nucleotide	S_chemicals	O
analogues	analogues	O	O
adefovir	adefovir	O	O
and	and	O	O
tenofovir	tenofovir	S_chemicals	O
remained	remained	O	O
effective	effective	O	O
in	in	O	O
suppressing	suppressing	O	O
viral	viral	O	O
replication	replication	O	O
in	in	O	O
vitro	vitro	O	O
.	.	O	O

These	these	O	O
findings	findings	O	O
reveal	reveal	O	O
the	the	O	O
differential	differential	O	O
impact	impact	O	O
of	of	O	O
immune	immune	O	O
escape	escape	O	O
variants	variants	O	O
on	on	O	O
the	the	O	O
replication	replication	O	O
and	and	O	O
drug	drug	S_chemicals	O
susceptibility	susceptibility	O	O
of	of	O	O
complex	complex	O	O
HBV	hbv	O	O
mutants	mutants	O	O
,	,	O	O
supporting	supporting	O	O
the	the	O	O
need	need	O	O
of	of	O	O
close	close	O	O
surveillance	surveillance	O	O
and	and	O	O
treatment	treatment	O	O
adjustment	adjustment	O	O
in	in	O	O
response	response	O	O
to	to	O	O
the	the	O	O
selection	selection	O	O
of	of	O	O
distinct	distinct	O	O
mutational	mutational	O	O
patterns	patterns	O	O
.	.	O	O

